Find Academic Supervisors

Matthew J SnyderView profile

Associate Clinical Professor

• Medical Education
• Family Medicine
• Obstetrics
• +1 more

Lt Col Matthew Snyder, DO, FAAFP, serves as Program Director of the Nellis Family Medicine Residency at Mike O'Callaghan Federal Hospital, Nellis AFB, Las Vegas, NV. He holds dual academic appointments as Associate Clinical Professor at Uniformed Services University of the Health Sciences (USUHS) School of Medicine and Assistant Clinical Professor at Saint Louis University School of Medicine within the Department of Family Medicine. July 2011 – June 2012: Faculty Development Fellowship, University of North Carolina Chapel Hill Aug 2008 – July 2009: Family Medicine/Obstetrics Fellowship, Swedish Family Medicine Residency, Seattle, WA June 2005 – June 2008: Eglin Family Medicine Residency, Eglin AFB, FL Aug 2001 – May 2005: D.O., Michigan State University College of Osteopathic Medicine Aug 1999 – June 2001: M.S. Anatomy, Pennsylvania State University Aug 1993 – May 1997: B.S. Pre-med (cum laude), Bob Jones University Dr. Snyder's research centers on Medical Education and Family Medicine , with specialized expertise in Obstetrics and Internal Medicine . His clinical focus includes evidence-based management of pre-eclampsia, diabetic neuropathy, and women's health issues, emphasizing practical applications for primary care physicians through rigorous clinical inquiry and educational frameworks. Analysis of his publications reveals consistent contributions to evidence-based family medicine literature, predominantly in American Family Physician and Journal of Family Practice . His work spans obstetric complications (pre-eclampsia, chorioamnionitis), internal medicine conditions (pericarditis, neuropathic pain), and clinical decision-making tools, demonstrating integration of military medicine perspectives with civilian best practices. No scientific awards were documented in the source material. With extensive teaching experience across military and international settings, Dr. Snyder has mentored medical students and residents during deployments to Bagram, Afghanistan, and service in three countries. His leadership roles include Program Director at Nellis Family Medicine Residency (2017–present), Military Program Director at Saint Louis University (2014–2017), and prior positions as Obstetrics Director and Assistant Program Director. Specific grant details were not provided. As leader of the Nellis Family Medicine Residency, Dr. Snyder directs a comprehensive military training program integrating clinical care, operational medicine, and academic scholarship at Mike O'Callaghan Federal Hospital. His team trains future military family physicians through a curriculum emphasizing deployment readiness alongside civilian medical competencies, maintaining strong affiliations with USUHS and Saint Louis University academic frameworks.

• Microfluidics
• Lab-on-a-chip technology
• Analytical chemistry
• +7 more

Jörg P. Kutter is a Professor in the Department of Pharmacy at the University of Copenhagen, where he leads the Microscale Analytical Systems research group. His work focuses on the design and development of lab-on-a-chip devices and microfluidic systems for analytical applications across biomedical, pharmaceutical, environmental and industrial fields. Professor Kutter's research expertise spans multiple areas of microfluidics and analytical chemistry. He specializes in chemical separation techniques including chromatography and electrophoresis, as well as FIA-based systems and integration of optical detection elements. His current work emphasizes microfabricated lab-on-a-chip systems with focus on separation and sample preparation techniques, and advanced micro and nano liquid handling. His research group has developed numerous applications using thiol-ene based microfluidic platforms, which have become a signature technology in his laboratory. Analysis of Professor Kutter's recent publications (2022-2024) reveals a strong progression from fundamental microfluidic techniques toward increasingly complex biological applications. His work now prominently features DNA analysis (particularly extrachromosomal circular DNA), olfactory mucus analysis using humanized yeast biosensors, pulmonary delivery of siRNA-loaded nanoparticles, glycopeptide enrichment for inflammation-related protein analysis, and microfluidic steroidogenesis assays. This evolution demonstrates the maturation of microfluidics technology and its growing impact on biomedical research and clinical diagnostics. Professor Kutter has secured several millions of Euros in funding support for national and international (EU) projects. He served as coordinator for a European STREP project (2007-2010) with seven partners and a European IP (2010-2015) with 16 partners. He has supervised 14 post-doctoral fellows, 20 PhD students, and 12 master's theses, demonstrating a strong commitment to academic mentoring and research training. He serves as Deputy editor for Electrophoresis and is a member of the Board of Directors of the Chemical and Biological Microsystems Society. He participates in technical program committees for major conferences including µ-TAS, MEMS, MSB and Transducers. Additionally, he acts as a scientific advisor for the Institute for Microtechnology in Mainz, Germany, and evaluates proposals for national and international funding agencies as well as educational accrediting agencies.

• Public Health
• Preventive Medicine
• Caregiver Studies
• +5 more

José Bruno Alves serves as an Assistant Professor and Coordinating Professor at the Jean Piaget School of Health in Vila Nova de Gaia, Portugal. His academic career spans multiple disciplines including nursing, psychology, and public health, with a strong focus on caregiver support systems and health promotion initiatives across European contexts. Education: Doctorate in Preventive Medicine and Public Health (2016) from University of Santiago de Compostela, Faculty of Medicine and Dentistry (with honors and laud) Master's Degree in Clinical and Health Psychology (2009) from Maia University Institute Degree in Psychology (2007) from Lusíada University of Porto Degree in Nursing (2003) from Santa Maria School of Nursing Postgraduate Degree in Health Services Administration and Management (2016) Postgraduate Degree in Human Resources Management (2016) Currently pursuing Master's Degree in Medical-Surgical Nursing with specialization in Care for People in Perioperative Situations Dr. Alves' research centers on caregiver studies, particularly focusing on informal caregivers, young caregivers, and their psychosocial needs. His work explores innovative approaches to health promotion, including digital health solutions for patients with chronic conditions like Parkinson's and Alzheimer's disease. His research integrates public health policy, health informatics, and clinical practice to develop comprehensive support systems for caregivers across multiple European countries. His scholarly output demonstrates a clear trajectory toward understanding caregiver experiences and developing evidence-based interventions. His publications span qualitative studies, policy evaluations, and technology-driven solutions, with a consistent emphasis on improving quality of life for both caregivers and care recipients. Recent work focuses on breast cancer screening among informal caregivers and the development of digital tools for health literacy enhancement. Scientific Recognition: Doctorate with honors and laud from University of Santiago de Compostela As Principal Investigator and researcher, Dr. Alves has led multiple European projects including Young Caregivers Project (POISE), Prolepsis (breast cancer screening for caregivers), EDY-CARE (social inclusion of young carers), and ICT4LIFE (technology for dementia care). His collaborative work spans Portugal, Spain, Sweden, Cyprus, and other European nations, demonstrating significant international research impact. Dr. Alves actively participates in policy development through his work with the Intersectoral Monitoring and Evaluation Committee for the Informal Caregiver Statute in Portugal, contributing to national legislation affecting approximately 800,000 informal caregivers. His leadership extends to professional organizations including PERION (Northern Perioperative Nurses Association) and Eurocarers in Brussels, where he served on the Executive Board from 2017-2023.

• Public Health
• Geriatrics
• Emergency Medicine
• +5 more

Shahrzad H Bazargan serves as an Adjunct Professor in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles. With a research career spanning over three decades, her work has consistently focused on health disparities, particularly among vulnerable populations including African American older adults and residents of under-resourced communities. Dr. Bazargan's research interests encompass public health, geriatrics, emergency medicine, and substance-related disorders, with a strong emphasis on health equity. Her scholarly contributions reveal a sustained commitment to addressing the unique healthcare challenges faced by minority populations. She has conducted extensive research on cancer screening disparities, intimate partner violence, mental health issues among elderly African Americans, and more recently, on community-based interventions to address health disparities during the COVID-19 pandemic. Analysis of her publication history shows a consistent research trajectory focused on health disparities among minority populations, particularly African Americans. Her work demonstrates an evolution from studying basic health behaviors and screening practices in the 1990s and early 2000s toward more complex community-based interventions in recent years. The 2024 publication on mobilizing faith-based health ambassadors represents the current direction of her research, focusing on culturally tailored interventions to address health disparities in underserved communities during public health emergencies. Dr. Bazargan has maintained an active research program with publications spanning multiple high-impact journals in public health, emergency medicine, and geriatrics. Her work often involves community-based participatory research approaches, collaborating with community organizations and faith-based institutions to develop culturally appropriate health interventions. Her research has been supported by various grants focused on health disparities, though specific grant details are not provided in the available information. Dr. Bazargan has collaborated extensively with researchers including Mohsen Bazargan, Tommi Gaines, and Roberto Vargas, indicating a strong network of interdisciplinary collaborators focused on minority health issues. Dr. Bazargan's work demonstrates a sustained commitment to improving health outcomes for underserved populations through rigorous research and community engagement. Her recent focus on pandemic response in minority communities reflects her ability to adapt her expertise to emerging public health challenges while maintaining her focus on health equity.

• Machine Learning
• Biostatistics
• Epigenetics
• +4 more

Selçuk KORKMAZ is an Associate Professor in the Department of Biostatistics at Trakya University Faculty of Medicine. His interdisciplinary research bridges computational methods with biomedical applications, focusing on machine learning approaches for biological data analysis. Educational Background: Bachelor's Degree (2008): Ege University Faculty of Science, Department of Statistics Master's Degree (2011): Ege University Faculty of Medicine, Department of Biostatistics and Medical Informatics Doctoral Degree (2016): Hacettepe University Faculty of Medicine, Department of Biostatistics Dr. Korkmaz's research primarily focuses on machine learning applications in biostatistics, with particular emphasis on epigenetics, proteomics, and computer-aided drug design. His work demonstrates strong interdisciplinary connections between computational methods and clinical applications. He has developed novel approaches for biological assembly evaluation and protein-protein interface analysis during his visiting scientist position at the RCSB Protein Data Bank (University of California, San Diego) from April 2015 to March 2016. His recent publication trend shows a strong focus on developing computational tools (particularly R packages) for biomedical data analysis, with significant contributions in protein data bank interfaces, chemical database access, and biological variation analysis. His work spans multiple disciplines including bioinformatics, medical imaging analysis, and drug discovery applications. Dr. Korkmaz has served as an Assistant Professor at Trakya University since 2017 and was promoted to Associate Professor in 2021. Prior to this, he worked as a Research Assistant at Hacettepe University Faculty of Medicine Department of Biostatistics from June 2012 to November 2016.

• Autism Spectrum Disorder
• Attention Deficit Hyperactivity Disorder
• Specific Learning Disorders
• +3 more

Hasan Cem Aykutlu is an Assistant Professor in the Department of Child and Adolescent Psychiatry at Trakya University's Faculty of Medicine. He holds a Doctoral Degree (2017), Master's Degree (2013), and completed medical training at Ege University Faculty of Medicine. His research focuses on neurodevelopmental and behavioral disorders in children, with expertise in Autism Spectrum Disorder (ASD), ADHD, learning disabilities, and digital media impacts on adolescent mental health. His work emphasizes clinical psychiatry, epidemiological studies, and psychopharmacology. Recent publications explore: ASD diagnostic models and pandemic-related challenges ADHD treatment outcomes and eating behaviors Digital eye strain and screen addiction in adolescents Genetic underpinnings of neurodevelopmental disorders Dr. Aykutlu contributes to national programs for ASD recognition and has investigated psychiatric comorbidities in specialized populations (e.g., gifted children, oncology patients). No awards, grants, or student advisements are documented in the provided materials.

Jamie J. BernardView profile

Associate Professor

• Carcinogenesis
• Immunotoxicology
• Pharmacology
• +4 more

Jamie J. Bernard is an Associate Professor in the Department of Pharmacology and Toxicology at Michigan State University's College of Natural Science. His research focuses on obesity-promoted carcinogenesis , particularly how visceral fat inflammation drives cancer progression through the FGF2/FGFR1 pathway . He leads initiatives in chemoprevention using purified natural products and collaborates on biomarker development for adiposity-associated cancer risk. PhD in Toxicology (University of Rochester, 2009) Postdoctoral training in Dermatology (UC San Diego, 2009-2011) and Chemical Biology (Rutgers, 2011-2015) Research explores metabolic-immune crosstalk in cancer development, with recent work on: Translational relevance of FGF2 as a cancer risk biomarker Chemopreventive compound screening Adiposity-modifiable risk factors Publications demonstrate interdisciplinary focus across metabolic oncology , inflammation , and experimental methods . The lab actively recruits graduate students for precision prevention research and seeks collaborations in natural product development . Affiliated with the MSU Cancer Center and the Molecular Therapeutics Program.

Lonnie A. NelsonView profile

Professor

• Health Disparities
• Indigenous Health
• Aging and Cognition
• +5 more

Dr. Lonnie A. Nelson is a Professor in the Cancer Prevention Program within the Public Health Sciences Division at Fred Hutchinson Cancer Center and serves as Faculty Lead for the Indigenous Cancer Health Equity Initiative. A descendant of the Eastern Band of Cherokee Indians, he directs community-centered research addressing critical health disparities in American Indian and Alaska Native communities through culturally grounded approaches. His academic credentials include: Postdoctoral Fellowship in Rehabilitation Neuropsychology, Harborview Medical Center (2006) PhD in Clinical Psychology, University of Arizona (2004) MA in Clinical Psychology, University of Arizona (2000) BA in Psychology, University of Arizona (1997) Dr. Nelson's research portfolio centers on eliminating health inequities through community-based participatory research frameworks. His primary focus areas include cancer prevention initiatives (tobacco cessation, lung cancer screening), cognitive aging and dementia in urban Indigenous elders, cardiovascular risk linked to sleep health, opioid use disorder treatment retention, and suicide prevention. He emphasizes that researchers must serve communities and follow their lead in all scientific endeavors. As principal investigator of the U19 CANOE Partnership cooperative agreement, he oversees a comprehensive research program advancing cancer awareness, navigation, and equitable outcomes for Indigenous populations while cultivating the next generation of Indigenous health equity researchers. His work operates through the Indigenous Cancer Health Equity Initiative and CANOE Partnership teams, which integrate academic researchers, healthcare providers, and community stakeholders to co-develop culturally responsive interventions addressing systemic health barriers.

Yingye ZhengView profile

Professor

• Biostatistics
• Cancer Biomarker Research
• Medical Decision-Making
• +6 more

Dr. Yingye Zheng is a Professor in the Biostatistics Program within the Public Health Sciences Division at Fred Hutchinson Cancer Center (Fred Hutch) and an Affiliate Professor of Biostatistics at the University of Washington School of Public Health and Community Medicine. She serves as the Contact Principal Investigator for the Early Detection Research Network (EDRN) Data Management and Coordinating Center and is a Member of the Translational Data Science Integrated Research Center (TDS IRC) at Fred Hutch. Dr. Zheng earned her PhD in Biostatistics from the University of Washington in 2002, following an MS in Biostatistics (1999), an MA in Psychology from Washington University in St. Louis (1997), and a BS in Psychology from Peking University (1992). Her research focuses on developing novel statistical tools for medical decision-making related to disease screening, diagnosis, prognosis, and outcome prediction. Dr. Zheng specializes in evaluating the clinical utility of biomarkers and risk models with censored time-to-event outcomes, dynamic risk prediction using longitudinal biomarkers, and evaluating cancer screening processes using electronic medical records. Her work is deeply integrated with national research networks including the EDRN and PROSPR (Population-Based Research Optimizing Screening through Personalized Regimens). Dr. Zheng's extensive publication record demonstrates leadership in statistical methodology for cancer biomarker research, particularly in prostate cancer active surveillance, liquid biopsy technologies, and cancer screening trial design. Her recent work has focused on improving randomized cancer screening trials, polygenic risk scores, and novel approaches to biomarker validation with time-to-event outcomes. Fellow of the American Statistical Association (2021) Principal Investigator for $7.5 million NCI grant for cancer screening statistical coordination center Co-Principal Investigator for Patient-Centered Outcomes Research Institute (PCORI) research grant on randomized screening trial design Lead Statistician for the Prostate cancer Active Surveillance Study (PASS) Principal Investigator for Liquid Biopsy Consortium Data Management and Coordinating Unit As Director of COMPASS (Coordinating Multiple Projects in Applied Statistical Science), Dr. Zheng leads multi-center studies in public health research, providing statistical methodology, data management, and study coordination for several large-scale research networks. Her Zheng Lab develops statistical software packages for biomarker validation and risk prediction, including R packages like survAccuracyMeasures, partlyconditional, and longsurvAccuracyMeasures.

John K. LeeView profile

Associate Professor

• Genitourinary Oncology
• Prostate Cancer Research
• Bladder Cancer Research
• +5 more

John K. Lee, MD, PhD is an Associate Professor-in-Residence at the David Geffen School of Medicine at UCLA, holding dual appointments in the Department of Medicine (Division of Hematology/Oncology) and Department of Urology (Institute for Urologic Oncology). He maintains active clinical practice at Westwood Urology and hospital affiliations with Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center. His educational background includes an A.B. with highest honors in Biochemical Sciences from Harvard University (2001), MD from Geisel School of Medicine at Dartmouth (2006), PhD in Molecular Biology from UCLA (2016), residency in Internal Medicine at Boston Medical Center (2009), and fellowship in Hematology/Oncology at UCLA (2013-2014). Harvard University: A.B. Biochemical Sciences (2001) Geisel School of Medicine: MD (2006) UCLA: PhD Molecular Biology (2016) Dr. Lee specializes in genitourinary oncology with clinical focus on advanced prostate and bladder cancer. His research examines genotype-phenotype relationships in cancer through combinatorial genetics approaches while developing novel immunotherapies including antibody-drug conjugates, CAR-T cells, and TCR-T cell therapies. Current investigations target STEAP1 and CEACAM5 biomarkers to enhance treatment efficacy for neuroendocrine prostate cancer variants. Analysis of his recent publications reveals a strong trajectory toward clinical translation of immunotherapies, with increasing focus on tumor microenvironment modulation and biomarker-driven therapeutic strategies since 2021. His work bridges basic cancer biology with engineered immune solutions, particularly for treatment-resistant genitourinary malignancies. Major scientific recognition includes election to the American Society for Clinical Investigation (2024), NIH Director's New Innovator Award (2021), and Kleberg Foundation Medical Research Award (2022). His laboratory (@jklee_lab) has secured significant funding through Department of Defense Career Development Awards, NCI Experimental Therapeutics Program partnerships, and multiple Prostate Cancer Foundation grants. NIH Director's New Innovator Award (2021) ASCI Young Physician-Scientist Award (2020) SBUR Young Investigator Award (2020) DoD Peer-Reviewed Cancer Research Program Award (2019) Dr. Lee leads a federally funded basic and translational research laboratory within the UCLA Jonsson Comprehensive Cancer Center, focusing on developing immune-based strategies for prostate and bladder cancer. His team employs combinatorial genetics and immunopeptidomic profiling to identify therapeutic targets, with recent emphasis on tumor-localized cytokine delivery and engineered T cell receptors. Current projects include optimizing STEAP1-targeted CAR-T therapies and CEACAM5 antibody-drug conjugates for neuroendocrine prostate cancer variants.

• Colorectal Cancer Screening
• Gastroenterology
• Endoscopy
• +3 more

Joseph C. Anderson, MD, serves as Professor of Medicine at Dartmouth College's Geisel School of Medicine, with additional appointment as Associate Professor of Medicine at University of Connecticut School of Medicine. His clinical and research focus centers on gastrointestinal oncology and endoscopic screening methodologies. His academic training includes: B.S.E. in Engineering from University of Pennsylvania (1984) M.D. from Mount Sinai School of Medicine (1988) Internal Medicine residency at Stony Brook University (1991) Gastroenterology fellowship at Stony Brook University (1996) Dr. Anderson's research program investigates colorectal neoplasia detection mechanisms, with emphasis on flat and sessile serrated adenomas, smoking-related cancer risks, and optimization of colonoscopic screening techniques. His work has directly influenced national clinical guidelines through contributions to the American College of Gastroenterology's colorectal cancer screening protocols. Analysis of his 2009-2011 publications reveals consistent focus on endoscopic imaging advancements, population-based screening efficacy, and risk stratification for colorectal cancer. His research frequently employs high-definition colonoscopy in asymptomatic cohorts to identify precancerous lesions and evaluate demographic variables. No scientific awards were documented in the source materials. While student mentorship and grant funding details were not specified, his collaborative multi-institutional studies indicate active research leadership. Laboratory and team affiliations were not explicitly referenced in available documentation.

Alan SaghatelianView profile

Professor

• Metabolomics
• Peptide Biology
• Mass Spectrometry
• +7 more

Alan Saghatelian is a Professor and holds the Dr. Frederik Paulsen Chair at the Salk Institute for Biological Studies, where he leads the Clayton Foundation Laboratory for Peptide Biology. His research focuses on the discovery and characterization of natural small molecules, particularly metabolites and peptides, using advanced mass spectrometry techniques. Dr. Saghatelian received his Bachelor of Science in Chemistry from the University of California, Los Angeles, and his Ph.D. in Chemistry from The Scripps Research Institute. He completed his postdoctoral training as a Merck Fellow with the Life Sciences Research Foundation. His research program distinguishes itself through its focus on biology related to metabolites and peptides, which he refers to as natural small molecules. These molecules have vital roles in human physiology and disease but have been historically understudied due to technical challenges in their detection. Saghatelian's lab has made significant discoveries, including the identification of FAHFAs (fatty acid esters of hydroxy fatty acids), a novel class of lipids with anti-inflammatory properties that can reverse diabetes symptoms in mice. His team has also discovered thousands of human genes encoding microproteins that could advance our understanding of molecular pathways controlling diseases such as cancer and autoimmunity. Dr. Saghatelian's work spans multiple disease areas, with significant contributions to diabetes research, cancer biology, neurodegenerative diseases, and immunological disorders. His laboratory collaborates extensively with other researchers at Salk to understand the role of peptides and metabolites across various biological contexts. Mark Foundation for Cancer Research Endeavor Award (2022) American Association for the Advancement of Science Fellow (2020) Sloan Foundation Fellow (2011) Searle Scholars Program Award (2008) New Innovator Award, National Institutes of Health (2007) Burroughs Wellcome Fund Career Award in Biomedical Sciences (2005) Dr. Saghatelian's laboratory has been highly productive, with numerous publications in top-tier journals. His recent work has focused on microprotein discovery, lipid signaling molecules like FAHFAs, and the application of advanced proteomics and metabolomics techniques to understand disease mechanisms. His research program demonstrates a strong trajectory of innovation, moving from fundamental discoveries of new biological molecules to potential therapeutic applications. The Saghatelian Lab develops and applies novel mass spectrometry strategies to measure changes in small molecules that are often overlooked by traditional biological methods focusing on DNA, RNA, and proteins. The lab's work has revealed previously unknown aspects of human biology, including novel signaling pathways and regulatory mechanisms mediated by small molecules.

Joel A. OkoliView profile

Professor

• Surgical Oncology
• Breast Cancer
• Endoscopy
• +4 more

Dr. Joel A. Okoli is a Professor of Clinical Surgery specializing in Surgical Oncology at Morehouse School of Medicine. He practices at Grady Memorial Hospital in Atlanta, Georgia, where he provides surgical care for patients with various cancers and complex surgical conditions. As a board-certified surgeon by the American Board of Surgery, Dr. Okoli has established himself as a leader in cancer surgery and medical education at one of the nation's premier historically black medical institutions. Education: Doctor of Medicine (MD) from Yale University Master of Public Health (MPH) from Yale University Bachelor of Science in Clinical Chemistry from Seattle University General Surgery Residency at State University of New York at Buffalo School of Medicine Fellowships in Endoscopy & Vascular Access and Surgical Oncology at Roswell Park Cancer Institute Dr. Okoli's research interests focus on surgical oncology with particular expertise in breast cancer, colorectal cancer, and endocrine tumors. His work explores innovative diagnostic approaches for BRCA1-associated triple negative breast cancer, lymphedema monitoring using 3D scanning technology, and rehabilitation models for postoperative breast cancer patients. He has made significant contributions to understanding tumor suppressor pathways and metastasis mechanisms in various cancers. His publication record demonstrates a consistent focus on improving outcomes for cancer patients, particularly in underserved populations. Recent work has centered on precision diagnostics, rehabilitation models, and prognostic markers in breast and colorectal cancers. His research bridges laboratory discoveries with clinical applications, emphasizing translational approaches to cancer care. Scientific Awards: 2019 Morehouse School of Medicine Leonard Tow Gold Humanism in Medicine Award 2019 Morehouse School of Medicine Outstanding Surgery Faculty Member 2018 Morehouse School of Medicine Humanism and Excellence in Teaching Award 2017 Morehouse School of Medicine General Surgery Residency Program Outstanding Faculty Teaching Award 2017 Grady Health Systems Press Ganey Superstars Board recognition 2016 Morehouse School of Medicine Surgical Program Director's Outstanding Faculty Award As an educator and mentor, Dr. Okoli has received consistent recognition for his dedication to medical student and resident education. His "Biggest Smile Award" from the MD Class of 2014 reflects his commitment to student excellence and supportive teaching style. While specific grant information isn't detailed in the provided materials, his research portfolio suggests involvement in studies focused on cancer disparities and innovative surgical approaches. Dr. Okoli is actively involved in the Surgical Oncology division at Morehouse School of Medicine, where he contributes to clinical care, research, and education. His work with the Prospective Surveillance Model for breast cancer rehabilitation indicates participation in multidisciplinary teams focused on improving long-term outcomes for cancer survivors.

Julian D. LangerView profile

Researcher

• Mass Spectrometry
• Structural Biology
• Proteomics
• +5 more

Dr. Julian D. Langer serves as Group Leader and Head of Mass Spectrometry at the Max Planck Institute of Biophysics and Max Planck Institute for Brain Research in Frankfurt. His laboratory specializes in developing advanced mass spectrometry workflows and methods to address complex questions in structural biology, molecular neurobiology, and membrane protein research. Funded by both Max Planck Institutes, his lab operates eight state-of-the-art instruments from Bruker, Thermo, and Waters coupled to nano-UPLCs and analytical UPLCs. Dr. Langer's research focuses on three primary areas: direct sequencing of membrane protein complexes, hydrogen/deuterium exchange mass spectrometry (HDX-MS) for studying membrane protein dynamics, and proteome profiling in neuronal systems. His group has made significant contributions to identifying novel subunits in membrane protein complexes, characterizing ligand binding sites, and monitoring proteome remodeling in homeostatic synaptic plasticity. He is particularly known for developing specialized MALDI-TOF/TOF techniques that allow acquisition of information-rich PSD MS/MS spectra up to m/z 9000. His recent work demonstrates significant trends toward neuroproteomics and small protein discovery , with numerous publications on synaptic proteome mapping, neuronal ribosome dynamics, and detection of novel small proteins in prokaryotes. His research bridges structural biology, neurobiology, and analytical chemistry, with applications spanning from basic membrane protein mechanisms to neurological disorders. Dr. Langer actively collaborates with numerous research groups and is a member of DFG's SPP 2002 (Small proteins in prokaryotes) and BMBF's MOEL-SOEL program. He has developed specialized methodologies including BONCAT technology for proteome turnover studies and workflows for cell-type specific proteome analysis from living animals. His laboratory maintains strong connections with instrument vendors and has successfully extended HDX-MS techniques to large membrane protein complexes. Current research directions include investigating protein synthesis in neuronal processes, characterizing molecular components in specialized cellular systems like Sepia chromatophores, and developing next-generation mass spectrometry approaches for biomolecular analysis.

Katie DeCicco-SkinnerView profile

Professor

• Cancer Biology
• Molecular Oncology
• Tumor Microenvironment
• +6 more

Katie DeCicco-Skinner is a Professor in the Biology Department at American University's College of Arts and Sciences, where she leads the DeCicco-Skinner Cancer Biology Lab. Her research focuses on molecular mechanisms of cancer development with particular emphasis on tumor microenvironment interactions. She has secured substantial research funding including multiple NIH R15 grants, NASA Space Grants, and American University Mellon Grants through 2025. Her research program spans two primary areas: (1) investigating the tumor suppressor role of Tpl2 in squamous cell carcinoma development, and (2) examining how obesity contributes to multiple myeloma progression through adipocyte-tumor interactions. Her laboratory employs a range of molecular, cellular, and in vivo approaches to understand the signaling pathways involved in cancer initiation and progression. Analysis of her recent publications (2022-2024) reveals a continued focus on Tpl2 signaling in skin cancer and obesity-related mechanisms in multiple myeloma, with expanding research into HIV-1 maturation processes and angiogenesis. Her work bridges basic molecular mechanisms with potential therapeutic applications, particularly in understanding drug resistance mechanisms. Scientific Awards and Recognition: While specific awards aren't listed in the provided information, Dr. DeCicco-Skinner has received significant research funding including: American University Mellon Grant (2008, 2012, 2013, 2022, 2023, 2025) Faculty Research Support Grant (2011, 2015, 2017) NIH R15 grant (2R15CA152907-02 2015-2019) DC NASA Space Grant 2019 Dr. DeCicco-Skinner has mentored numerous undergraduate and graduate students, with over 50 student co-authors identified in her publication record. Her laboratory operates as an inclusive community of undergraduate, postbaccalaureate, and graduate students working collaboratively on cancer research. She has also contributed to media discussions about cancer research, including interviews with Washington Post, Doctor Radio/SiriusXM, and Science Daily.